Q-omics provides the consensus-scored RNF112 profile across patient tissues and cancer cell-line models. RNF112 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNF112 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, RNF112 RNA expression shows 15,361 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where RNF112 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF112 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF112 survival associations across molecular data types. RNF112 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF112 RNA expression–survival associations across cancer types. High RNF112 expression shows unfavorable associations in KIRP, COAD and ACC, but favorable associations in LGG, SKCM and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNF112 RNA expression.
This table summarizes RNF112 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNF112. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF112 shows lower tumor expression in COAD, BLCA, THCA, KICH, STAD and LUAD. The COAD box plot shows higher RNF112 RNA expression in normal versus tumor tissue (log2 FC = −1.156, t-test p < 0.001).
This table shows molecular features associated with RNF112 in patient tissues and cancer cell lines. In patient samples, RNF112 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF112 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
